Get the Stockscreener App
9.65
3.88%
0.36
After Hours:
9.50
-0.15
-1.55%
Adlai Nortye Ltd Adr stock is traded at $9.65, with a volume of 178.71K.
It is up +3.88% in the last 24 hours and up +506.92% over the past month.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
See More
Previous Close:
$9.29
Open:
$9.32
24h Volume:
178.71K
Relative Volume:
0.23
Market Cap:
$356.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.8298
EPS:
-2.5197
Net Cash Flow:
-
1W Performance:
-4.83%
1M Performance:
+506.92%
6M Performance:
+522.58%
1Y Performance:
+341.65%
1-Day Range:
$9.32
$10.12
1-Week Range:
$9.12
$10.77
52-Week Range:
$0.8786
$12.09
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
9.65 | 342.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - TipRanks
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World
TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World
Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World
Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat
Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India
Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - TipRanks
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm
Adlai Nortye (NASDAQ:ANL) Trading 1% HigherWhat's Next? - MarketBeat
Adlai Nortye (NASDAQ:ANL) Trading 1% Higher – What’s Next? - Defense World
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR Cash Flow – LS:A3EEED - TradingView — Track All Markets
Total common shares outstanding of Adlai Nortye Ltd. Sponsored ADR – LS:A3EEED - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Terns Pharmaceuticals (TERN) and Pyxis Oncology (PYXS) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Shares Down 1.4% – Here’s Why - Defense World
Adlai Nortye (NASDAQ:ANL) Shares Down 1.4%Here's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Vera Therapeutics (VERA) and Varex Imaging (VREX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Autolus Therapeutics (AUTL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM) - The Globe and Mail
H.C. Wainwright Reaffirms Their Hold Rating on Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Ltd. Plans Redomiciliation to Singapore - MSN
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
There is no financial data for Adlai Nortye Ltd Adr (ANL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):